Filana Therapeutics, Inc. (FLNA)
0.6556
+0.01
(+1.13%)
USD |
NASDAQ |
Oct 28, 16:00
0.6556
0.00 (0.00%)
After-Hours: 17:52
Filana Therapeutics Enterprise Value : -51.36M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | -51.36M |
| October 26, 2026 | -53.13M |
| October 23, 2026 | -51.98M |
| October 22, 2026 | -51.08M |
| October 21, 2026 | -50.83M |
| October 20, 2026 | -49.42M |
| October 19, 2026 | -49.74M |
| October 16, 2026 | -48.70M |
| October 15, 2026 | -45.93M |
| October 14, 2026 | -47.34M |
| October 13, 2026 | -46.77M |
| October 12, 2026 | -45.51M |
| October 09, 2026 | -43.22M |
| October 08, 2026 | -43.38M |
| October 07, 2026 | -43.28M |
| October 06, 2026 | -40.42M |
| October 05, 2026 | -40.66M |
| October 02, 2026 | -37.71M |
| October 01, 2026 | -36.06M |
| September 30, 2026 | -39.88M |
| September 29, 2026 | -38.01M |
| September 28, 2026 | -41.46M |
| September 25, 2026 | -46.54M |
| September 24, 2026 | -45.35M |
| September 23, 2026 | -40.65M |
| Date | Value |
|---|---|
| September 22, 2026 | -32.92M |
| September 21, 2026 | -46.96M |
| September 18, 2026 | -47.61M |
| September 17, 2026 | -47.90M |
| September 16, 2026 | -49.63M |
| September 15, 2026 | -49.03M |
| September 14, 2026 | -47.96M |
| September 11, 2026 | -45.36M |
| September 10, 2026 | -43.60M |
| September 09, 2026 | -43.60M |
| September 08, 2026 | -44.17M |
| September 04, 2026 | -43.06M |
| September 03, 2026 | -42.67M |
| September 02, 2026 | -41.25M |
| September 01, 2026 | -41.27M |
| August 31, 2026 | -39.30M |
| August 28, 2026 | -37.80M |
| August 27, 2026 | -38.09M |
| August 26, 2026 | -38.03M |
| August 25, 2026 | -36.85M |
| August 24, 2026 | -37.75M |
| August 21, 2026 | -36.26M |
| August 20, 2026 | -37.15M |
| August 19, 2026 | -36.01M |
| August 18, 2026 | -40.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CorMedix, Inc. | 509.14M |
| Eloxx Pharmaceuticals, Inc. | -8.120M |
| Breakthrough Chemistry, Inc. | 0.241M |
| BioStem Technologies, Inc. | 20.64M |
| Cardiac Biotech Solutions, Inc. | 5.690M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.603M |
| Total Expenses (Quarterly) | 8.603M |
| EPS Diluted (Quarterly) | -0.1781 |
| Earnings Yield | -133.5% |
| Normalized Earnings Yield | -133.50 |